LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study
LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study
复制标题
LBA1 通过 SP142、SP263 和 22C3 PD-L1 免疫组织化学 (IHC) 测定以及血液肿瘤突变负荷 (bTMB) 测定的 atezolizumab (atezo) 在生物标志物亚组中的临床疗效：IMpower110 研究结果
DOI：
10.1093/annonc/mdz453
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
J. Jassem
中科院分区：
文献类型：
--
作者：
R. Herbst;F. de Marinis;G. Giaccone;N. Reinmuth;A. Vergnenègre;C. Barrios;M. Morise;E. Felip;Z. Andrić;Sarayut Lucien Geater;M. Ozguroglu;S. Mocci;M. McCleland;W. Zou;I. Enquist;K. Komatsubara;Y. Deng;H. Kuriki;D. Spigel;J. Jassem
